AVITA Medical, Inc. (ASX:AVH) has disclosed it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, 5 November 2026, with a conference call and webcast scheduled for that day to discuss the results and recent business highlights.
Key Points
- Third quarter 2026 financial results to be released after U.S. market close on 5 November 2026
- Conference call and webcast scheduled for 1:30 p.m. Pacific Time on 5 November 2026
- Australian participants can join at 8:30 a.m. Australian Eastern Daylight Time on 6 November 2026
- A replay will be available on the Events page of the company's investor relations website following the live broadcast
Third Quarter 2026 Results Release Schedule
AVITA Medical disclosed that its third quarter 2026 financial results will be published after the close of the U.S. financial markets on Thursday, 5 November 2026. The company is listed on both the NASDAQ exchange under the ticker RCEL and on the ASX under the ticker AVH. The filing states the results release was authorised by the Chief Financial Officer of AVITA Medical, Inc. No financial figures or preliminary results were disclosed in the filing.
Conference Call and Webcast Details
AVITA Medical will host a conference call and webcast on 5 November 2026 at 1:30 p.m. Pacific Time, which corresponds to 8:30 a.m. Australian Eastern Daylight Time on Friday, 6 November 2026. The call will cover the company's financial results and recent business highlights. Participants can register in advance to receive dial-in details and a personal PIN. A replay will be made available on the Events page of the company's investor relations website for those unable to attend the live broadcast.
AVITA Medical Products and Approvals
According to the filing, AVITA Medical describes itself as a therapeutic acute wound care company. Its flagship product, RECELL, is approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. In the U.S., the company also holds exclusive rights to market Cohealyx, a collagen-based dermal matrix, and to manufacture and distribute PermeaDerm, a biosynthetic wound matrix. Internationally, RECELL and RECELL GO are CE-marked in Europe, hold TGA certification in Australia, are listed with Medsafe in New Zealand, and are PMDA-approved in Japan.





Please wait processing your request...